本文選題：企業(yè)并購　切入點：財務風險　出處：《河北經(jīng)貿大學》2017年碩士論文

【摘要】：近幾年,越來越多的企業(yè)把并購當作持續(xù)發(fā)展甚至是海外擴張的重要手段,然而并購是一把“雙刃劍”,成功的并購為企業(yè)資源的優(yōu)化配置帶來積極的作用,但是,如果并購沒有成功,企業(yè)很有可能降低資源的配置效率,以致會給并購雙方帶來很大的負面影響。隨著我國市場經(jīng)濟的不斷加深和國民經(jīng)濟的繁榮發(fā)展,近幾年并購案例在我國屢見不鮮,尤其是產(chǎn)業(yè)集中度較低的行業(yè),許多企業(yè)通過橫向并購進一步擴大市場份額。其中醫(yī)療行業(yè)就屬于眾多產(chǎn)業(yè)集中度較低的行業(yè)之一,隨著國民生活水平的提高,對醫(yī)療健康越來越重視,當前資源分散的醫(yī)療行業(yè)無法滿足市場的需求,行業(yè)內的并購整合勢在必行。同時,為增強我國藥企的規(guī)范管理,2011年3月國家推出了新版《藥品生產(chǎn)質量管理規(guī)范》(又稱新版GMP),新版GMP要求藥企在2016年1月1日前通過認證,否則將面臨停產(chǎn),而眾多中小企業(yè)憑借自身實力難以達到新版GMP的要求,企業(yè)若要在競爭激烈的行業(yè)中生存發(fā)展只有通過并購整合的方式。2013年1月16日華潤三九發(fā)布公告稱為落實公司發(fā)展戰(zhàn)略,擬收購桂林天和97.18%的股份,華潤三九收購桂林天和填補了其在骨科領域的空白,是典型的通過并購方式擴展企業(yè)市場的案例,在本次收購中,華潤三九因其對桂林天和估值溢價過高及全部使用現(xiàn)金支付等高財務風險作法受到各方質疑,本文通過搜集、整理、研究國內外學者關于并購財務風險的相關研究文獻,以及對此次并購案例始末的分析梳理,還原了華潤三九并購桂林天和的全過程,并運用并購財務風險的相關理論對這一案例中發(fā)生的并購前目標企業(yè)價值評估風險、并購中融資風險和支付風險及并購后的財務整合風險分析研究,得出華潤三九在并購桂林天和時存在較高的財務風險的結論,最后結合本案例中突出的財務風險提出防范和控制建議,為其他并購企業(yè)降低并購財務風險提供參考。
[Abstract]:In recent years, more and more enterprises regard M & A as an important means of sustainable development and even overseas expansion. However, M & A is a "double-edged sword". If M & A is not successful, the enterprise will probably reduce the efficiency of resource allocation, which will bring great negative effects to both sides of M & A. with the deepening of the market economy and the prosperity of the national economy in our country, In recent years, M & A cases are common in China, especially in industries with low industrial concentration. Many enterprises further expand their market share through horizontal mergers and acquisitions. Among them, medical industry is one of the industries with low industrial concentration. With the improvement of the standard of living of the people, more and more attention has been paid to medical care and health. At present, the medical industry with scattered resources cannot meet the needs of the market, so it is imperative to integrate mergers and acquisitions within the industry. At the same time, In order to strengthen the normative management of pharmaceutical enterprises in China, in March 2011, the state launched a new edition of the "quality Management Standard for Pharmaceutical production" (also known as the new edition of GMP, which requires pharmaceutical enterprises to pass the certification before January 1, 2016, otherwise, they will face suspension of production. However, many small and medium-sized enterprises cannot meet the requirements of the new version of GMP with their own strength. If enterprises want to survive and develop in a highly competitive industry, they can only adopt the way of merger and acquisition integration. On January 16, 2013, China Resources 39 issued an announcement calling it the implementation of the company's development strategy. To acquire the shares of Guilin Tianhe and 97.18%, China Resources 39's acquisition of Guilin Tianhe filled the gap in the field of orthopaedics. It is a typical case of expanding the enterprise market through mergers and acquisitions. In this acquisition, China Resources 39 has been questioned by all parties for its high financial risk practices such as excessive premium to Guilin Tianhe valuation and full use of cash payments. By collecting and sorting out, this paper studies the relevant research literature of domestic and foreign scholars on the financial risk of mergers and acquisitions. As well as the analysis of the beginning and end of this case, it restores the whole process of Tianhe merger of Guilin by China Resources 39, and applies the theory of financial risk of M & A to evaluate the value of the target enterprise before M & A in this case. The financial risk and payment risk in M & A and the financial integration risk after M & A are analyzed and studied, and the conclusion that China Resources 39 has high financial risk in the merger and acquisition of Guilin Tianhe is concluded. Finally, combining with the outstanding financial risk in this case, the paper puts forward some suggestions on how to prevent and control the financial risk, and provides reference for other M & A enterprises to reduce the financial risk of M & A.
【學位授予單位】：河北經(jīng)貿大學
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：F426.72;F271;F406.7
，

本文編號：1666639